

## AKEBIA THERAPEUTICS INC.

### CONNECTICUT DISCLOSURE INFORMATION

#### I. PURPOSE

On June 27, 2023, Connecticut Governor Ned Lamont signed into law HB 6669, a bill that requires pharmaceutical manufacturers, like Akebia Therapeutics, Inc. (Akebia), to disclose certain information to Prescribers in the course of conducting business. Specifically, this information includes:

- The list price of prescription drugs manufactured.

This information is to be provided in writing to all Prescribers licensed in the state of Connecticut, that Akebia conducts business with.

#### II. WHOLESALE ACQUISITION COST

PRODUCT NAME	MANUFACTURER	NDC	PKG SIZE
Auryxia Oral Tablet 1 GM 210 MG(Fe)	KERYX BIOPHARMACEUTICALS <sup>1</sup>	59922-0631-01	200
		WAC / PACK	\$1548.00
		WAC / TAB	\$7.74

---

<sup>1</sup> KERYX BIOPHARMACEUTICALS INC. IS A WHOLLY OWNED SUBSIDIARY OF AKEBIA THERAPEUTICS, INC.